Intra-arterial vs intra-venous thrombolysis for anterior cerebral occlusion

Canadian Journal of Neurological Sciences

Volumn 37, Issue 2, 2010, Pages 240-244

  Zhang, Bin ^a   Sun, Xiaojiang ^a   Li, Minghua ^a   Wang, Feng ^a   Xu, Dan ^a   Duan, Hao ^a   Fang, Chun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; INSULIN; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; NITROPRUSSIDE SODIUM;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CIRCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; DISABILITY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RANKIN SCALE; STROKE; SYMPTOM; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

EID: 76649117108     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009999     Document Type: Article

References (24)

1. The National Institute of Neurological Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587
2. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, et al. Dichotomized efficacy end points and global end-point analysis applied to the ECASS Intention-to-Treat Data Set: post hoc analysis of ECASS I. Stroke. 1998; 29:2073-2075
3. Hacke W, Bluhmki E, Steiner T, Tatlisumak T, Mahagne MH, Sacchetti ML, et al. Randomised double-blind placebocontrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352:1245-1251
4. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150
5. Albers GW, Clark WM, Madden KP, Hamilton SA. ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Stroke. 2002;33:493-495
6. Hacke W, Donnan G, Fieschi C, Kaste M, Von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774
7. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329
8. Wahlgren N, Ahmed N, Dávalos A, HackeW, Millán M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372 9646:1303-1309
9. Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke. 2002;33:2866-2871
10. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: prolyse in acute cerebral thromboembolism. JAMA. 1999;282:2003-2011
11. del Zoppo GJ, Poeck K, PessinMS,Wolpert SM, FurlanAJ, Ferbert A, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;(32):78-86.
12. Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20:12-17
13. Ezaki Y, Tsutsumi K, Onizuka M, Kawakubo J, Yagi N, Shibayama A, et al. Retrospective analysis of neurological outcomes after intra-arterial thrombolysis in basilar artery occlusion. Surg Neurol. 2003;60:423-430
14. Mielke O,Wardlaw J, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2004;18(4):CD000514.
15. Agarwal P, Kumar S, Hariharan S, Eshkar N, Verro P, Cohen B, et al. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis. 2004;17(2-3):182-190
16. Intraarterial thrombolysis: ready for prime time? Executive Committee of the ASITN. AJNR Am J Neuroradiol. 2001;22(1): 55-58
17. Mattle HP, Arnold M, Georgiadis D, Baumann C, Nedeltchev K, Benninger D, et al. Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign. Stroke. 2008;39:379-383
18. Alexandrov AV, Black SE, Ehrlich LE, Caldwell CB, Norris JW. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke. 1997;28:1198-1202
19. Toni D, Fiorelli M, Bastianello S, Sacchetti ML, Sette G, Argentino C, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996;46:341-345
20. Molina CA, Montaner J, Abilleira S, Ibarra B, Romero F, Arenillas JF, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke. 2001;32:1079-1084
21. Molina CA, Alvarez-Sabín J, Montaner J, Abilleira S, Arenillas JF, Coscojuela P, et al. Thrombolysis-related hemorrhagic infarction. Stroke. 2002;33:1551-1556
22. Neumann-Haefelin T, Du Mesnil De Rochemont R, Fiebach JB, Gass A, Nolte C, Kucinski T, et al. Effect of incomplete (Spontaneous and Postthrombolytic) recanalization after middle cerebral artery occlusion. A magnetic resonance imaging study. Stroke. 2004;35:109-114
23. The IMS Study Investigators. Haemorrhage in the interventional management of stroke study. Stroke. 2006;37:847-851
24. IMS Trial Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke. 2004;35:904-911